These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8187318)

  • 1. Serum growth hormone (GH) profiles after nasally administered GH in normal subjects and GH deficient patients.
    Møller J; Lauersen T; Mindeholm L; Hoelgaard A; Ovesen P; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):511-3. PubMed ID: 8187318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal absorption of growth hormone in normal subjects: studies with four different formulations.
    Laursen T; Ovesen P; Grandjean B; Jensen S; Jørgensen JO; Illum P; Christiansen JS
    Ann Pharmacother; 1994; 28(7-8):845-8. PubMed ID: 7949497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
    Hedin L; Olsson B; Diczfalusy M; Flyg C; Petersson AS; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1993 Apr; 76(4):962-7. PubMed ID: 8473411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):373-8. PubMed ID: 7514513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone.
    Laursen T; Jørgensen JO; Susgaard S; Møller J; Christiansen JS
    Ann Pharmacother; 1993 Apr; 27(4):411-5. PubMed ID: 8477114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.
    Jørgensen JO; Møller N; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jan; 70(1):207-14. PubMed ID: 2294131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).
    Laron Z; Frenkel J; Gil-Ad I; Klinger B; Lubin E; Wuthrich P; Boutignon F; Lengerts V; Deghenghi R
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):539-41. PubMed ID: 7955465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease.
    Toogood AA; Jones J; O'Neill PA; Thorner MO; Shalet SM
    Clin Endocrinol (Oxf); 1998 May; 48(5):569-76. PubMed ID: 9666868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity.
    Oscarsson J; Ottosson M; Johansson JO; Wiklund O; Mårin P; Björntorp P; Bengtsson BA
    Metabolism; 1996 Mar; 45(3):370-7. PubMed ID: 8606646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of concentration and injection volume on the bioavailability of subcutaneous growth hormone: comparison of administration by ordinary syringe and by injection pen.
    Blok GJ; van der Veen EA; Susgaard S; Larsen F
    Pharmacol Toxicol; 1991 May; 68(5):355-9. PubMed ID: 1946180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.
    Johansson JO; Oscarsson J; Bjarnason R; Bengtsson BA
    Metabolism; 1996 Mar; 45(3):362-9. PubMed ID: 8606645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.
    Janssen YJ; Frölich M; Roelfsema F
    Br J Clin Pharmacol; 1999 Mar; 47(3):273-8. PubMed ID: 10215751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different modes of growth hormone (GH) administration do not change GH binding protein activity in man.
    Ho KK; Jorgensen JO; Valiontis E; Waters MJ; Rajkovic IA; Christiansen JS
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):143-8. PubMed ID: 8435895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children.
    Portes ES; Oliveira JH; MacCagnan P; Abucham J
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):183-9. PubMed ID: 10931099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
    Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.